九典制藥(300705.SZ):將投資1.57億元建高端製劑研發產業園建設項目(一期)
格隆匯1月11日丨九典制藥(300705.SZ)公佈,隨着公司外用製劑產品銷售規模的快速增長,現有生產線產能已難以與快速增長的市場需求相匹配。考慮到公司長遠發展及未來產能佈局,公司將投資15741.72萬元建設高端製劑研發產業園建設項目(一期)。
隨着公司外用製劑產品銷售規模的快速增長,現有生產線產能已難以與快速增長的市場需求相匹配,本項目擬新建外用製劑生產線,進一步提高洛索洛芬鈉凝膠貼膏、酮洛芬凝膠貼膏生產能力,有利於進一步發揮公司技術、產品、客户、品牌和管理資源優勢,實現公司業務的整合及協同效應,通過充分實現規模化效應,切實增強公司盈利能力與可持續發展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.